The Additional Polycyclo Ring System Contains A 1,3-diazole [e.g., Bis (benzimidazol-2-yl) Stilene, Etc.] Patents (Class 548/305.4)
  • Patent number: 9200145
    Abstract: The present invention relates to a coupling agent for rubber/carbon black, containing a sulfide compound represented by the following chemical formula (I): (in the formula, each A represents O, S, NH or NR; each R represents a linear or branched alkyl or alkenyl group having 1 to 6 carbon atoms, or a cyclic alkyl or alkenyl group having 3 to 6 carbon atoms, and when A is NR, the plurality of R's on a condensed aromatic heterocyclic ring may be the same as or different from each other; n represents an integer from 1 to 6; and x represents an integer from 1 to 4).
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: December 1, 2015
    Assignee: SHIKOKU CHEMICALS CORPORATION
    Inventors: Yukiharu Shirakawa, Takeshi Masuda
  • Patent number: 9101669
    Abstract: Provided are a self-assembled conjugate of a host molecule containing compound and a guest molecule containing compound, a delivery composition of a bioactive material comprising the self-assembled conjugate and a bioactive material to be delivered, and a composition for tissue engineering containing the self-assembled conjugate and a cell.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: August 11, 2015
    Assignee: POSTECH ACADEMY-INDUSTRY FOUNDATION
    Inventors: Sei Kwang Hahn, Kimoon Kim, Hyuntae Jung, Jeong-A Yang, Kyeng Min Park
  • Publication number: 20150137084
    Abstract: Triptycene derivatives having symmetric or asymmetric substituents are provided. The triptycene derivatives of the present invention may be applied in phosphorescent lighting devices ranging from deep blue to red and may be applied as a host material, an electron transporting material or a hole transporting material. An OLED device is also herein disclosed.
    Type: Application
    Filed: May 19, 2014
    Publication date: May 21, 2015
    Applicant: National Tsing Hua University
    Inventors: Chien-Hong CHENG, Ho-Hsiu CHOU, Cheng-Chang LAI
  • Publication number: 20150123089
    Abstract: The present application provides a new nitrogen-containing heterocyclic compound and an organic electronic device using the same.
    Type: Application
    Filed: April 12, 2013
    Publication date: May 7, 2015
    Inventors: Dong Hoon Lee, Tae Yoon Park, Sung Kil Hong, Boonjae Jang, Minseung Chun, Dong Sik Kim, Minyoung Kang
  • Publication number: 20150090963
    Abstract: An organic compound represented by Formula 1 is disclosed. An organic light-emitting device including the organic compound is also disclosed.
    Type: Application
    Filed: February 25, 2014
    Publication date: April 2, 2015
    Applicant: SAMSUNG DISPLAY CO., LTD.
    Inventors: Young-Kook Kim, Kwang-Hyun Kim, Eun-Young Lee
  • Patent number: 8993778
    Abstract: A process for preparing telmisartan by reacting 2-n-propyl-4-methyl-6-(1?-methylbenzimidazol-2?-yl)benzimidazole with a compound of formula (IV) wherein Z is a leaving group, to obtain the compound 2-cyano-4?-[2?-n-propyl-4?-methyl-6?-(1??-methylbenzimidazol-2??-yl)benzimidazol-1?-ylmethyl]biphenyl, and subsequently hydrolyzing the nitrile function to obtain the acid function.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: March 31, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Norbert Hauel, Rolf Dach, Helmut Heitger, Oliver Meyer
  • Patent number: 8952177
    Abstract: The present invention relates to compounds of Formula (I), and solvates, hydrates, and pharmaceutically acceptable salts thereof, wherein X1, X1?, X1?, R1, R2 and R3 are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: February 10, 2015
    Assignee: Janssen Pharmaceutica NV
    Inventors: Wenying Chai, Curt A. Dvorak, Wendy Eccles, James P. Edwards, Steven D. Goldberg, Paul J. Krawczuk, Alec D. Lebsack, Jing Liu, Daniel J. Pippel, Zachary S. Sales, Virginia M. Tanis, Mark S. Tichenor, John J. M. Wiener
  • Publication number: 20150031884
    Abstract: The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection.
    Type: Application
    Filed: December 15, 2011
    Publication date: January 29, 2015
    Applicant: ABBVIE INC.
    Inventors: Allan C. Krueger, Warren M. Kati, Clarence J. Maring, Rolf Wagner, Charles W. Hutchins
  • Publication number: 20150024321
    Abstract: To provide an azo compound which improves the dispersibility of an azo pigment in a non-water soluble solvent. The purpose is achieved by an azo compound having a specific structure in which a high molecular weight polymer unit is bonded.
    Type: Application
    Filed: February 20, 2013
    Publication date: January 22, 2015
    Inventors: Masanori Seki, Yuki Hasegawa, Waka Hasegawa, Masashi Kawamura, Taiki Watanabe, Chiaki Nishiura, Takayuki Toyoda, Ayano Mashida, Yasuaki Murai, Masashi Hirose
  • Publication number: 20140364616
    Abstract: The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection.
    Type: Application
    Filed: December 15, 2011
    Publication date: December 11, 2014
    Applicant: ABBVIE INC.
    Inventors: Allan C. Krueger, Warren M. Kati, Clarence J. Maring, Rolf Wagner, Charles W. Hutchins
  • Publication number: 20140343286
    Abstract: The present invention relates to anti-HCV compounds, compositions comprising the same and methods of using the same to treat HCV infection.
    Type: Application
    Filed: December 15, 2011
    Publication date: November 20, 2014
    Inventors: Allan C. Krueger, Warren M. Kati, Clarence J. Maring, Rolf Wagner, Charles W. Hutchins
  • Publication number: 20140316144
    Abstract: The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: June 26, 2014
    Publication date: October 23, 2014
    Inventors: Elizabeth M. Bacon, Jeromy J. Cottell, John O. Link, Teresa Alejandra Trejo Martin
  • Patent number: 8859780
    Abstract: The present invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof; wherein R, R1, R2, R3, R4, m, and n are as defined herein, to pharmaceutical compositions comprising said compound, and to methods of treating diseases or conditions mediated by elevated persistent sodium current, such as an ocular disorder, multiple sclerosis, seizure disorder, and chronic pain.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: October 14, 2014
    Assignee: Allergan, Inc.
    Inventors: George R. Ehring, Ellen Chao, Herman Ng, Hau Ton, Jia Chian Li, Joseph S. Adorante, Michael S. Garst, Howard B. Rind, Mark R. Hansen, Alfred Arthur Avey, Jr., Lloyd Jay Dolby, Shervin Esfandiari, Vivian R. MacKenzie, Jeremiah Andrew Marsden, David Charles Muchmore
  • Publication number: 20140284584
    Abstract: Disclosed herein are compounds represented by the formula: where HT and n are defined herein. Compositions of said compounds along with organic light-emitting diode (OLED) devices related thereto are also disclosed.
    Type: Application
    Filed: March 25, 2014
    Publication date: September 25, 2014
    Applicant: NITTO DENKO CORPORATION
    Inventor: Shijun Zheng
  • Publication number: 20140243257
    Abstract: Compounds represented by formula I: or pharmaceutically acceptable salts and solvates thereof, wherein A, B, B?, X, Y, R1, R1?, R2, R2?, R3, R3?, R5, R5?, R6, m, n, or p are as defined herein, are useful for treating flaviviridae viral infections.
    Type: Application
    Filed: May 8, 2014
    Publication date: August 28, 2014
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: James A. Henderson, John Maxwell, Louis Vaillancourt, Mark Morris, Ronald Grey, JR., Simon Giroux, Laval Chan Chun Kong, Sanjoy Kumar Das, Bingcan Liu, Carl Poisson, Caroline Cadilhac, Monica Bubenik, T. Jagadeeswar Reddy, Guy Falardeau, Constantin Yannopoulos, Jian Wang, Oswy Z. Pereira, Youssef L. Bennani, Albert C. Pierce, Govinda Rao Bhisetti, Kevin M. Cottrell, Valerie Marone
  • Publication number: 20140231715
    Abstract: The present invention relates to a compound of the formula (I), to the use of this compound in an electronic device, and to an electronic device comprising one or more compounds of the formula (I). The invention furthermore relates to the preparation of the compound of the formula (I) and to a formulation comprising one or more compounds of the formula (I).
    Type: Application
    Filed: March 23, 2012
    Publication date: August 21, 2014
    Applicant: Merck Patent GmbH Patents & Scientific Information
    Inventors: Philipp Stoessel, Arne Buesing, Frank Voges, Christof Pflumm, Amir Hossain Parham, Thomas Eberle, Teresa Mujica-Fernaud
  • Patent number: 8809313
    Abstract: The present disclosure provides substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes, of Formula I D-M-D??(Formula I) useful as antiviral agents. In certain embodiments disclosed herein M is a group —P-A-P— where A is Certain substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. Pharmaceutical compositions/and combinations containing one or more substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes and a pharmaceutically acceptable carrier are also provided by this disclosure. Methods for treating viral infections, including Hepatitis C viral infections are provided by the disclosure.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: August 19, 2014
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Qiuping Wang, Akihiro Hashimoto, Godwin Pais, Xiangzhu Wang, Venkat Gadhachanda, Avinash Phadke, Milind Deshpande, Dawei Chen
  • Patent number: 8779156
    Abstract: Compounds represented by formula I or pharmaceutically acceptable salts thereof, wherein A, B, B?, X, Y, R1, R2, R2?, R3, R3?, R4, R4?, R5, R5?, m, n, or p are as defined herein, are useful for treating flaviviridae viral infections.
    Type: Grant
    Filed: September 24, 2012
    Date of Patent: July 15, 2014
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Sanjoy Kumar Das, Youssef L. Benanni, Laval Chan Chun Kong, John Maxwell, T. Jagadeeswar Reddy, Constantin Yannopoulos, Bingcan Liu, Caroline Cadilhac, Simon Giroux, James A. Henderson, Real Denis, Louis Vaillancourt, Oswy Z. Pereira, Carl Poisson, Guy Falardeau, Mark A. Morris
  • Patent number: 8765731
    Abstract: Compounds represented by formula I: or pharmaceutically acceptable salts and solvates thereof, wherein A, B, B?, X, Y, R1, R1?, R2, R2?, R3, R3?, R5, R5?, R6, m, n, or p are as defined herein, are useful for treating flaviviridae viral infections.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: July 1, 2014
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: James A. Henderson, John Maxwell, Louis Vaillancourt, Mark Morris, Ronald Grey, Jr., Simon Giroux, Laval Chan Chun Kong, Sanjoy Kumar Das, Bingan Liu, Carl Poisson, Caroline Cadilhac, Monica Bubenik, T. Jagadeeswar Reddy, Guy Falardeau, Constantin Yannopoulos, Jian Wang, Oswy Z. Pereira, Youssef L. Bennani, Albert C. Pierce, Govinda Rao Bhisetti, Kevin M. Cottrell, Valerie Marone
  • Publication number: 20140163237
    Abstract: Some embodiments provide a compound represented by Formula 1: wherein R1, R2, R3, R4, R5, R6, R7 and R8 are independently H, C1-C3 alkyl, or C1-3 perfluoroalkyl; HT is optionally substituted carbazoyl, optionally substituted phenylcarbazolyl, optionally substituted (phenylcarbazolyl)phenyl, optionally substituted phenylnaphthylamine, or optionally substituted diphenylamine; and ET optionally substituted benzimidazol-2-yl, optionally substituted benzothiazol-2-yl, optionally substituted benzoxazol-2-yl, optionally substituted 3,3?-bipyridin-5-yl, optionally substituted quinolin-8-yl, optionally substituted quinolin-5-yl, or optionally substituted quinoxalin-5-yl. Other embodiments provide an organic light-emitting diode device comprising a compound of Formula 1.
    Type: Application
    Filed: December 10, 2013
    Publication date: June 12, 2014
    Applicant: NITTO DENKO CORPORTION
    Inventors: David T. Sisk, Shijun Zheng
  • Publication number: 20140155541
    Abstract: The present invention relates to a coupling agent for rubber/carbon black, containing a sulfide compound represented by the following chemical formula (I): (in the formula, each A represents O, S, NH or NR; each R represents a linear or branched alkyl or alkenyl group having 1 to 6 carbon atoms, or a cyclic alkyl or alkenyl group having 3 to 6 carbon atoms, and when A is NR, the plurality of R's on a condensed aromatic heterocyclic ring may be the same as or different from each other; n represents an integer from 1 to 6; and x represents an integer from 1 to 4).
    Type: Application
    Filed: July 20, 2012
    Publication date: June 5, 2014
    Applicant: SHIKOKU CHEMICALS CORPORATION
    Inventors: Yukiharu Shirakawa, Takeshi Masuda
  • Publication number: 20140135322
    Abstract: The present invention relates to novel chemical compounds formula (I) (C)n—B-(A)m-B—(C)n (I) wherein m is 0 or 1, and n is independently 0, 1, 2 or 3, A, each B and each C are independently selected from phenylene and five- and six-membered heteroaromatic rings, and for a terminal ring B or C also from bicyclic heteroaromatic fused rings having seven to ten ring members, wherein the bond between at least two of the rings A to C may be replaced by a carbonyl group (—CO—), wherein at least two of the rings A to C are substituted with one or two groups R, and wherein each ring A to C further optionally is substituted with one or two groups R1. The compounds are useful in therapy, especially therapy of a mammal suffering from a disease involving misfolded or aggregated forms of proteins.
    Type: Application
    Filed: July 13, 2012
    Publication date: May 15, 2014
    Inventors: Peter Asberg, Kristin Hammer, Johan Olsson, Martin Henriksson
  • Publication number: 20140100245
    Abstract: Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by the Arenavirus family is disclosed.
    Type: Application
    Filed: November 27, 2013
    Publication date: April 10, 2014
    Applicant: SIGA TECHNOLOGIES, INC.
    Inventors: Dongcheng Dai, DENNIS E. HRUBY, TOVE C. BOLKEN, SEAN M. AMBERG, TRAVIS K. WARREN
  • Patent number: 8691999
    Abstract: An improved process for the preparation of telmisartan, or a pharmaceutically acceptable salt thereof, comprises subjecting 1H-Benzimidazole-2-n-propyl-4-methyl-6-(1?-methyl benzimidazole-2?yl)] of formula (II), and methyl-4-(bromomethyl)biphenyl-2-carboxylate of formula (III) to condensation and hydrolysis in a single step:
    Type: Grant
    Filed: May 10, 2005
    Date of Patent: April 8, 2014
    Assignee: Cipla Limited
    Inventors: Rajendra Narayanrao Kankan, Dharmaraj Ramachandra Rao, Srinivas Laxminarayan Pathi, Ravikumar Puppala
  • Patent number: 8623347
    Abstract: Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by the Arenavirus family is disclosed.
    Type: Grant
    Filed: January 14, 2009
    Date of Patent: January 7, 2014
    Assignee: Siga Technologies, Inc.
    Inventors: Dongcheng Dai, Dennis E. Hruby, Tove C. Bolken, Sean M. Amberg, Travis K. Warren
  • Patent number: 8623899
    Abstract: Inhibitors of HCV replication of formula I including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R and R? have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HCV inhibitors, in HCV therapy.
    Type: Grant
    Filed: August 6, 2010
    Date of Patent: January 7, 2014
    Assignee: Janssen Research & Development Ireland
    Inventors: David McGowan, Samuel Dominique Demin, Stefaan Julien Last, Koen Vandyck, Pierre Jean-Marie Bernard Raboisson
  • Publication number: 20130317213
    Abstract: The present disclosure relates to methods for making compounds useful in the treatment of Hepatitis C virus (HCV) infection.
    Type: Application
    Filed: August 1, 2013
    Publication date: November 28, 2013
    Inventors: Shawn K. Pack, Steven Tymonko, Bharat P. Patel, Kenneth J. Natalie, JR., Makonen Belema
  • Publication number: 20130317047
    Abstract: The present invention relates to use of an inhibitor of the renin-anglotensin system (RAS) or a pharmaceutically acceptable derivative thereof, such as ramipril or ramiprilat, in the prevention of stroke, diabetes and/or congestive heart failure (CHF).
    Type: Application
    Filed: November 9, 2012
    Publication date: November 28, 2013
    Applicant: Aventis Pharma Deutschland GmbH
    Inventor: Aventis Pharma Deutschland GmbH
  • Publication number: 20130295049
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: October 30, 2012
    Publication date: November 7, 2013
    Applicant: ENANTA PHARMACEUTICALS, INC
    Inventor: ENANTA PHARMACEUTICALS, INC
  • Patent number: 8563738
    Abstract: Ligands useful for promoting copper-catalyzed azide-alkyne cycloaddition reactions comprise a compound represented by structural Formula (I) as described in the specification, wherein in Formula (I) Z1 is a nitrogen-containing heterocyclic group or a group represented by the formula: Y1—(CH2)c—Y2—(CH2)d—Y3—CH2—N(CH2Z4)(CH2Z5), where Y1 is -E1-C(O)O—, -E1-C(O)NH—, -E1-, or a covalent bond; Y2 is a covalent bond, —CH?CH—, or a 1,4-(1,2,3-triazolyl) group; Y3 is —OC(O)-E2-, —NHC(O)-E2-, -E2-, or a covalent bond; each of E1 and E2 is a benzimidazolyl group attached at the 1 and 2 positions; each of c and d is independently 1, 2, 3, 4, or 5; each of Z2, Z3, Z4 and Z5 is a nitrogen-containing heterocyclic group including a substituent X1 and optionally including a substituent (CH2)n—R1, and Y1, Y2, Y3, X1, R1, c, d and n are each as defined in the specification.
    Type: Grant
    Filed: September 15, 2008
    Date of Patent: October 22, 2013
    Assignee: The Scripps Research Institute
    Inventors: M. G. Finn, Valentin O. Rodionov
  • Publication number: 20130190508
    Abstract: Novel N-heterocyclic carbene ligand precursors, N-heterocyclic carbene ligands and N-heterocyclic metal-carbene complexes are provided. Metal-carbene complexes comprising N-heterocyclic carbene ligands can be chiral, which are useful for catalyzing enantioselective synthesis. Methods for the preparation of the N-heterocyclic carbene ligands and N-heterocyclic metal-carbene complexes are given.
    Type: Application
    Filed: March 8, 2013
    Publication date: July 25, 2013
    Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventor: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
  • Publication number: 20130190373
    Abstract: A pharmaceutical composition for prophylaxis or treatment of systemic diseases in cats, wherein the composition comprising administration of a therapeutically effective amount of angiotensin II receptor 1 (AT-1) antagonist (sartan) to a cat in need of such a treatment.
    Type: Application
    Filed: March 13, 2013
    Publication date: July 25, 2013
    Applicant: Boehringer Ingelheim Vetmedica GmbH
    Inventor: Boehringer Ingelheim Vetmedica GmbH
  • Publication number: 20130172570
    Abstract: This present invention provides a method of making benzazoles comprising a process of making aryl or alkyl benzazoles from corresponding aryl acid chlorides or alkyl acid chlorides without applying hazard condensing agent. The benzazole compounds described in this invention have following formula I: Wherein: n is an integer of from 3 to 8; Z is O, NR or S; and R and R? are individually hydrogen; alkyl of from 1 to 24 carbon atoms, for example, propyl, t-butyl, heptyl, and the like; aryl or hetero-atom substituted aryl of from 5 to 20 carbon atoms, for example, phenyl and naphthyl, furyl, thienyl, pyridyl, quinolinyl and other heterocyclic systems; or halo such as chloro, fluoro, bromo, cyano; or atoms necessary to complete a fused aromatic ring; and B is a linkage unit consisting of alkyl, aryl, substituted alkyl, or substituted aryl which conjugately or unconjugately connects the multiple benzazoles together.
    Type: Application
    Filed: February 15, 2012
    Publication date: July 4, 2013
    Applicant: US Government as Represented by the Secretary of the ARMY
    Inventors: Jianmin Shi, Eric W. Forsythe, David C. Morton
  • Publication number: 20130164258
    Abstract: The present invention relates to novel Tricyclic Compounds, compositions comprising at least one Tricyclic Compound, and methods of using Tricyclic Compounds for treating or preventing a viral infection or a virus-related disorder in a patient. The present invention provides Tricyclic Compounds of Formula (I): Non-limiting examples of the Compounds of Formula (I) include compound 44 The Compounds of Formula (II) can be useful for inhibiting HCV viral replication or replicon activity, and for treating or pre-venting HCV infection in a patient.
    Type: Application
    Filed: May 28, 2010
    Publication date: June 27, 2013
    Inventors: Kevin X. Chen, Anilkumar Gopinadhan Nair, Qingbei Zeng, Stuart B. Rosenblum, Joseph A. Kozlowski, F. George Njoroge
  • Publication number: 20130157997
    Abstract: Compounds represented by formula I: or pharmaceutically acceptable salts and solvates thereof, wherein A, B, B?, X, Y, R1, R1?, R2, R2?, R3, R3?, R5, R5?, R6, m, n, or p are as defined herein, are useful for treating flaviviridae viral infections.
    Type: Application
    Filed: November 16, 2012
    Publication date: June 20, 2013
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventor: Vertex Pharmaceuticals Incorporated
  • Publication number: 20130153874
    Abstract: Provided are an organic electroluminescence device, which: shows high luminous efficiency; is free of any pixel defect; and has a long lifetime, and a material for an organic electroluminescence device for realizing the device. The material for an organic electroluminescence device is a compound of a specific structure having a ?-conjugated heteroacene skeleton crosslinked with a carbon atom, nitrogen atom, or oxygen atom. The organic electroluminescence device has one or more organic thin film layers including a light emitting layer between a cathode and an anode, and at least one layer of the organic thin film layers contains the material for an organic electroluminescence device.
    Type: Application
    Filed: February 5, 2013
    Publication date: June 20, 2013
    Applicant: IDEMITSU KOSAN CO., LTD.
    Inventor: IDEMITSU KOSAN CO., LTD.
  • Patent number: 8461351
    Abstract: A sterically bulky stabilizer that includes an alkylated-benzimidazolone compound, where the sterically bulky stabilizer is associated non-covalently with a benzimidazolone pigment, and the presence of the sterically bulky stabilizer limits the extent of particle growth and aggregation, to afford nanoscale pigment particles.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: June 11, 2013
    Assignees: Xerox Corporation, National Research Council of Canada
    Inventors: Rina Carlini, Darren Andrew Makeiff
  • Publication number: 20130137878
    Abstract: A process for preparing telmisartan by reacting 2-n-propyl-4-methyl-6-(1?-methylbenzimidazol-2?-yl)benzimidazole with a compound of formula (IV) wherein Z is a leaving group, to obtain the compound 2-cyano-4?-[2?-n-propyl-4?-methyl-6?-(1??-methylbenzimidazol-2??-yl)benzimidazol-1?-ylmethyl]biphenyl, and subsequently hydrolyzing the nitrile function to obtain the acid function.
    Type: Application
    Filed: January 25, 2013
    Publication date: May 30, 2013
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Norbert HAUEL, Rolf DACH, Helmut HEITGER, Oliver MEYER
  • Publication number: 20130126791
    Abstract: The present invention relates to a polymer which contains at least one structural unit which has electron-transport properties, to processes for the preparation thereof and to mixtures (blends), solutions and formulations which comprise these polymers. Furthermore, the present invention relates to the use of these polymers in electronic devices, in particular in organic electro-luminescent devices, so-called OLEDs (OLED=organic light emitting diodes), and to these organic electroluminescent devices themselves. The polymers according to the invention exhibit improved efficiency, in particular on use in OLEDs.
    Type: Application
    Filed: July 8, 2011
    Publication date: May 23, 2013
    Applicant: Merck Patent GmbH
    Inventors: Susanne Heun, Aurélie Ludemann, Rémi Manouk Anémian
  • Patent number: 8445693
    Abstract: One embodiment disclosed in the invention is the efficient synthesis of halogenated biaryl starting material via Grignard chemistry and the use thereof. Another embodiment of the invention is the reaction of catalyzed carbonylation of the 3?-(2?-halo-biphenyl-4-ylmethyl)-1,7?-dimethyl-2?-propyl-1H,3?H-[2,5?]bibenzoimidazolyl (TLMH) using either gaseous carbon monoxide in a solvent mixture containing water; or formic acid salts optionally together with acetic acid in anhydrous solvent.
    Type: Grant
    Filed: March 19, 2009
    Date of Patent: May 21, 2013
    Assignee: Lek Pharmaceuticals D.D.
    Inventors: Zdenko Casar, Anton Copar, Jerome Cluzeau, Andrej Premrl
  • Publication number: 20130112946
    Abstract: A heterocyclic compound represented by Formula 1 below and an organic light-emitting device including the heterocyclic compound: wherein X1 and X2, X1 and R1 to R10 are defined as in the specification.
    Type: Application
    Filed: February 29, 2012
    Publication date: May 9, 2013
    Applicant: SAMSUNG MOBILE DISPLAY CO., LTD.
    Inventors: Bum-Woo Park, Yoon-Hyun Kwak, Sun-Young Lee, Chang-Ho Lee, Se-Jin Cho
  • Publication number: 20130115193
    Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Application
    Filed: November 8, 2012
    Publication date: May 9, 2013
    Applicant: Bristol-Myers Squibb Company
    Inventor: Bristol-Myers Squibb Company
  • Publication number: 20130105769
    Abstract: A condensed-cyclic compound represented by Formula 1, and an organic light-emitting device including the condensed-cyclic compound. wherein R1 and R2, Ar1 through Ar4, L1 and L2, X1 and X2, and a and b are defined as in the specification.
    Type: Application
    Filed: May 22, 2012
    Publication date: May 2, 2013
    Applicant: SAMSUNG MOBILE DISPLAY CO., LTD.
    Inventors: Jin-O Lim, Seok-Hwan Hwang, Young-Kook Kim, Hye-Jin Jung, Sang-Hyun Han, Soo-Yon Kim, Hee-Joo Ko
  • Publication number: 20130102788
    Abstract: The present invention relates to efficient synthetic method of 1,3,5-tris (N-Phenylbenzimidazole) Benzene and pertains to the field of synthesis of organic light-emitting materials. The method and process of the patent are as following: 1,3,5-tris (N-Phenyl-N Phenylammonium) Benzamide is treated by shrinking agent but no high temperature required, and then high purity product can be reached after raw material dissolved. The reaction only takes a few minutes and through recrystallization the purity can be over 99%, and then the material with stable crystal phase reached after sublimation step. The method introduced by the present patent is easy to operate, and with high in yield and purity, which adapt industrial production and has important significance for the industrialization.
    Type: Application
    Filed: February 9, 2011
    Publication date: April 25, 2013
    Applicants: BEIJING AGLAIA TECHNOLOGY DEVELOPMENT CO., LTD., GUANGDONG AGLAIA OPTOECTRONIC MATERIALS CO., LTD.
    Inventors: Lifei Cai, Lei Dai, Hongyu Zhao, Yanfeng Ding, Weilong Zhang, Junhao Lian
  • Patent number: 8410285
    Abstract: A process for obtaining 2?-halo-4-methylbiphenyls is described, which comprises reacting 4 halotoluene with a 1,2-dihalobenzene in the presence of elemental metal such as magnesium, lithium or zinc, wherein 0 to 0.9 molar, particularly 0 to 0.2 molar excess of 4-halotoluene in regard to 1,2-dihalobenzene is used, and arised organometal intermediates are quenched by elemental mental halogen. In addition, the coupling of arised 2?-halo-4-methylbiphenyls with 2-(1-propyl)-4-methyl-6-(1?-methylbenzimidazole-2-il)benzimidazole to afford 3?-(2?-halo-biphenyl-4-ylmethyl)-1,7?-dimethyl-2?-propyl-1H,3?H-[2,5?]bibenzoimidazolyl, which can be further converted to organometallic compound and said organometallic compound is further reacted with formic acid derivative, such as N,N-dimethylformamide, alkylformiate or carbon dioxide to obtain telmisartan, is also described.
    Type: Grant
    Filed: March 19, 2009
    Date of Patent: April 2, 2013
    Assignee: LEK Pharmaceuticals D.D.
    Inventors: Anton Copar, Zdenko Casar, Andrej Premrl
  • Publication number: 20130066252
    Abstract: The invention relates to a method for diagnosis of multiple sclerosis (MS) wherein, presence or absence of an anti-AT1 receptor antibody is determined in a sample from a patient to be diagnosed and wherein, the presence of an anti-AT1-receptor antibody is indicative of the disease.
    Type: Application
    Filed: April 12, 2011
    Publication date: March 14, 2013
    Applicant: CELLTREND GMBH
    Inventor: Harald Heidecke
  • Publication number: 20130056075
    Abstract: Provided is a compound of formula (I): wherein A is C2-3 alkylene; m is an integer ranging from 2 to 25; and n is an integer ranging from 3 to 10. An electrolyte for a dye-sensitized solar cell having the compound of formula (I) and/or a compound of formula (II) is further provided for increasing photoelectric conversion efficiency.
    Type: Application
    Filed: September 4, 2012
    Publication date: March 7, 2013
    Applicant: EVERLIGHT USA, INC.
    Inventors: Yu-Hui Lee, Hsin-Ying Lu, Kuan-Wei Lee, Tzu-Heng Ko
  • Publication number: 20130059852
    Abstract: Some embodiments of this invention include methods for treating disease and methods for administering a compound of Formula (I). In some aspects of the invention, diseases can be treated by administration of compositions comprising a compound of Formula (I). Pharmaceutical compositions of some embodiments of the present invention comprise a compound of Formula (I).
    Type: Application
    Filed: April 8, 2011
    Publication date: March 7, 2013
    Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
    Inventors: John O. Trent, Jason B. Meier, Kelby B. Napier
  • Publication number: 20130053558
    Abstract: The invention relates to compounds of the formula (1), to a method for producing compounds of the formula (1), to the use of the compounds in electronic devices and to electronic devices containing compounds according to formula (1), preferably as electron transport materials, as matrix materials, as electron blocking materials or as emitting materials.
    Type: Application
    Filed: October 14, 2010
    Publication date: February 28, 2013
    Applicant: Merck Patent GmbH
    Inventors: Christof Pflumm, Arne Buesing, Amir Hossain Parham, Rocco Fortte, Holger Heil, Philipp Stoessel, Teresa Mujica-Fernaud
  • Patent number: 8362269
    Abstract: The invention relates to a process for preparing 1,7?-dimethyl-2?-propyl-2,5?-bi-1H-benzimidazole of formula (I)
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: January 29, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Richard Ehlenz, Oliver Meyer, Hartmut Schmidt